Background: Acute myeloid leukemia (AML) is a clonal disease characterized by the
proliferation and accumulation of myeloid progenitor cells in the bone marrow, which …

Acute myeloid leukemia (AML) is a heterogeneous disorder among hematologic
malignancies. Several genetic alterations occur in this disease, which cause proliferative …

Cytarabine (ara-C) is the key agent for treating acute myeloid leukemia (AML). After being
transported into leukemic cells by human equilibrative nucleoside transporter 1 (hENT1), ara …

Background Despite advances in novel therapeutics, supportive care, and postremission
therapy, the outcome of high-risk and elderly patients as well as those with …

Cytarabine (ara-C) is the key drug for treatment of acute myeloid leukemia. Since
intracellular cytarabine triphosphate (ara-CTP) is an active metabolite of ara-C, factors that …

For the last twenty years, significant progress in Molecular and Cellular Biology has resulted
in a better characterization and understanding of the biology and prognosis of acute myeloid …

Barasertib, an aurora B inhibitor, terminates cell division, introduces polyploidy, and
consequently causes apoptosis. In the present study, we evaluated the effect of the …

Mutations of the nucleophosmin (NPM-1) gene have been reported in 50–60% of acute
myeloid leukemia (AML) patients with normal karyotype. This work was designed to study …

Gemtuzumab ozogamicin (GO) consists of the CD 33 antibody linked to calicheamicin. The
binding of GO to the CD 33 antigen on leukemic cells results in internalization followed by …

Molecular Biomarkers in Cytogenetically Normal –Acute Myeloid Leukemia: harnessing the
targets Page 1 Review Article Open Access Molecular Biomarkers & Diagnosis Sharma and …